Efficacy of satralizumab therapy in the treatment of NMOSD

Małgorzata Krzyżanowska; Katarzyna Kozon; Jakub Olszewski; Andrzej Patyra

doi:10.56782/pps.166

Data publikacji : 2023-09-22

Tom 21 Nr 3 (2023)

Efficacy of satralizumab therapy in the treatment of NMOSD

Małgorzata Krzyżanowska

Katarzyna Kozon

Jakub Olszewski

Andrzej Patyra

DOI: https://doi.org/10.56782/pps.166

Abstrakt

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.

Inne teksty tego samego autora

Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)
Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Tom 20 Nr 1 (2022)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Andrzej Patyra, Marcin Kołakowski, Marta Katarzyna Dudek, Anna Karolina Kiss, Isolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L. , Prospects in Pharmaceutical Sciences: Tom 20 Nr 2 (2022)
Andrzej Patyra, Grzegorz Witkowski, Voltage-gated sodium channels mutations and their role in epilepsy , Prospects in Pharmaceutical Sciences: Tom 20 Nr 1 (2022)
Andrzej Patyra, Twenty years of Prospects in Pharmaceutical Sciences: recent changes , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Katarzyna Herjan, Piotr Armański, Jakub Olszewski, Magdalena Sitnik, Maciej Bara, POSITIVE IMPACT OF TRANEXAMIC ACID IN VARIOUS MEDICAL SETTINGS , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF

Zasady cytowania

Krzyżanowska, M., Kozon, K., Olszewski, J., & Patyra, A. (2023). Efficacy of satralizumab therapy in the treatment of NMOSD. Prospects in Pharmaceutical Sciences, 21(3), 64–68. https://doi.org/10.56782/pps.166